Collectively, these findings demonstrate that FOXM1 targeting disrupts the metabolic status and stemness features of CTCL cells via JNK activation, thereby offering novel insights into potential therapeutic strategies for overcoming therapeutic challenges in CTCL. The gene discussed is MAPK8; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.